

Liposomal and Lipid-based Nanoparticle Drug Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/LC9999DB22F3EN.html>

Date: February 2022

Pages: 116

Price: US\$ 3,250.00 (Single User License)

ID: LC9999DB22F3EN

Abstracts

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

This report contains market size and forecasts of Liposomal and Lipid-based Nanoparticle Drug in Global, including the following market information:

Global Liposomal and Lipid-based Nanoparticle Drug Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Liposomal and Lipid-based Nanoparticle Drug market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Liposomes Drugs Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Liposomal and Lipid-based Nanoparticle Drug include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang,

Zydus Cadila, TTY Biopharma and Pacira, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposomal and Lipid-based Nanoparticle Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Liposomal and Lipid-based Nanoparticle Drug Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, by Type, 2021 (%)

Liposomes Drugs

Lipid Nanoparticle Drugs

Global Liposomal and Lipid-based Nanoparticle Drug Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, by Application, 2021 (%)

Hospital

Retail Pharmacy

Other

Global Liposomal and Lipid-based Nanoparticle Drug Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Liposomal and Lipid-based Nanoparticle Drug revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Liposomal and Lipid-based Nanoparticle Drug revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Liposomal and Lipid-based Nanoparticle Drug Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL LIPOSOMAL AND LIPID-BASED NANOPARTICLE DRUG OVERALL MARKET SIZE

- 2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size: 2021 VS 2028
- 2.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Liposomal and Lipid-based Nanoparticle Drug Players in Global Market
- 3.2 Top Global Liposomal and Lipid-based Nanoparticle Drug Companies Ranked by Revenue
- 3.3 Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Companies
- 3.4 Top 3 and Top 5 Liposomal and Lipid-based Nanoparticle Drug Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Liposomal and Lipid-based Nanoparticle Drug Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Liposomal and Lipid-based Nanoparticle Drug Players in Global Market
 - 3.6.1 List of Global Tier 1 Liposomal and Lipid-based Nanoparticle Drug Companies

3.6.2 List of Global Tier 2 and Tier 3 Liposomal and Lipid-based Nanoparticle Drug Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Liposomal and Lipid-based Nanoparticle Drug Market Size Markets, 2021 & 2028

4.1.2 Liposomes Drugs

4.1.3 Lipid Nanoparticle Drugs

4.2 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts

4.2.1 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2022

4.2.2 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2023-2028

4.2.3 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Retail Pharmacy

5.1.4 Other

5.2 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts

5.2.1 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2022

5.2.2 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2023-2028

5.2.3 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Market Size, 2021

& 2028

6.2 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts

6.2.1 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2022

6.2.2 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2023-2028

6.2.3 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028

6.3.2 US Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.3.3 Canada Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.3.4 Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028

6.4.2 Germany Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.3 France Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.4 U.K. Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.5 Italy Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.6 Russia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.7 Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.4.8 Benelux Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028

6.5.2 China Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.5.3 Japan Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.5.4 South Korea Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.5.5 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.5.6 India Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028

- 6.6.2 Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028
- 6.6.3 Argentina Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028
- 6.7 Middle East & Africa
 - 6.7.1 By Country - Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028
 - 6.7.2 Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028
 - 6.7.3 Israel Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028
 - 6.7.4 Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028
 - 6.7.5 UAE Liposomal and Lipid-based Nanoparticle Drug Market Size, 2017-2028

7 PLAYERS PROFILES

- 7.1 Johnson & Johnson
 - 7.1.1 Johnson & Johnson Corporate Summary
 - 7.1.2 Johnson & Johnson Business Overview
 - 7.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.1.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.1.5 Johnson & Johnson Key News
- 7.2 Sun Pharmaceutical
 - 7.2.1 Sun Pharmaceutical Corporate Summary
 - 7.2.2 Sun Pharmaceutical Business Overview
 - 7.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.2.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.2.5 Sun Pharmaceutical Key News
- 7.3 CSPC
 - 7.3.1 CSPC Corporate Summary
 - 7.3.2 CSPC Business Overview
 - 7.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.3.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.3.5 CSPC Key News
- 7.4 Kinyond
 - 7.4.1 Kinyond Corporate Summary
 - 7.4.2 Kinyond Business Overview

- 7.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
- 7.4.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
- 7.4.5 Kinyond Key News
- 7.5 Teva
 - 7.5.1 Teva Corporate Summary
 - 7.5.2 Teva Business Overview
 - 7.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.5.4 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.5.5 Teva Key News
- 7.6 Fudan-Zhangjiang
 - 7.6.1 Fudan-Zhangjiang Corporate Summary
 - 7.6.2 Fudan-Zhangjiang Business Overview
 - 7.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.6.5 Fudan-Zhangjiang Key News
- 7.7 Zydus Cadila
 - 7.7.1 Zydus Cadila Corporate Summary
 - 7.7.2 Zydus Cadila Business Overview
 - 7.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.7.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.7.5 Zydus Cadila Key News
- 7.8 TTY Biopharma
 - 7.8.1 TTY Biopharma Corporate Summary
 - 7.8.2 TTY Biopharma Business Overview
 - 7.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
 - 7.8.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)
 - 7.8.5 TTY Biopharma Key News
- 7.9 Pacira
 - 7.9.1 Pacira Corporate Summary
 - 7.9.2 Pacira Business Overview
 - 7.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.9.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.9.5 Pacira Key News

7.10 Luye Pharma

7.10.1 Luye Pharma Corporate Summary

7.10.2 Luye Pharma Business Overview

7.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.10.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.10.5 Luye Pharma Key News

7.11 Leadiant Biosciences

7.11.1 Leadiant Biosciences Corporate Summary

7.11.2 Leadiant Biosciences Business Overview

7.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.11.5 Leadiant Biosciences Key News

7.12 Ipsen

7.12.1 Ipsen Corporate Summary

7.12.2 Ipsen Business Overview

7.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.12.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.12.5 Ipsen Key News

7.13 Sayre Therapeutics

7.13.1 Sayre Therapeutics Corporate Summary

7.13.2 Sayre Therapeutics Business Overview

7.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.13.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.13.5 Sayre Therapeutics Key News

7.14 Jazz

7.14.1 Jazz Corporate Summary

7.14.2 Jazz Business Overview

7.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.14.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market

(2017-2022)

7.14.5 Jazz Key News

7.15 Alnylam

7.15.1 Alnylam Corporate Summary

7.15.2 Alnylam Business Overview

7.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.15.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.15.5 Alnylam Key News

7.16 Bausch Health

7.16.1 Bausch Health Corporate Summary

7.16.2 Bausch Health Business Overview

7.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.16.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.16.5 Bausch Health Key News

7.17 Acrotech Biopharma

7.17.1 Acrotech Biopharma Corporate Summary

7.17.2 Acrotech Biopharma Business Overview

7.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.17.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.17.5 Acrotech Biopharma Key News

7.18 Takeda

7.18.1 Takeda Corporate Summary

7.18.2 Takeda Business Overview

7.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.18.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.18.5 Takeda Key News

7.19 Chiesi Farmaceutici

7.19.1 Chiesi Farmaceutici Corporate Summary

7.19.2 Chiesi Farmaceutici Business Overview

7.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.19.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.19.5 Chiesi Farmaceutici Key News

7.20 Gilead Sciences

7.20.1 Gilead Sciences Corporate Summary

7.20.2 Gilead Sciences Business Overview

7.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings

7.20.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue in Global Market (2017-2022)

7.20.5 Gilead Sciences Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Liposomal and Lipid-based Nanoparticle Drug Market Opportunities & Trends in Global Market

Table 2. Liposomal and Lipid-based Nanoparticle Drug Market Drivers in Global Market

Table 3. Liposomal and Lipid-based Nanoparticle Drug Market Restraints in Global Market

Table 4. Key Players of Liposomal and Lipid-based Nanoparticle Drug in Global Market

Table 5. Top Liposomal and Lipid-based Nanoparticle Drug Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Share by Companies, 2017-2022

Table 8. Global Companies Liposomal and Lipid-based Nanoparticle Drug Product Type

Table 9. List of Global Tier 1 Liposomal and Lipid-based Nanoparticle Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Liposomal and Lipid-based Nanoparticle Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2023-2028

Table 30. Johnson & Johnson Corporate Summary

Table 31. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 32. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 33. Sun Pharmaceutical Corporate Summary

Table 34. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 35. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 36. CSPC Corporate Summary

Table 37. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 38. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 39. Kinyond Corporate Summary

Table 40. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 41. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 42. Teva Corporate Summary

Table 43. Teva Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 44. Teva Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 45. Fudan-Zhangjiang Corporate Summary

Table 46. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 47. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 48. Zydus Cadila Corporate Summary

Table 49. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 50. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 51. TTY Biopharma Corporate Summary

Table 52. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 53. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 54. Pacira Corporate Summary

Table 55. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 56. Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 57. Luye Pharma Corporate Summary

Table 58. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 59. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 60. Leadiant Biosciences Corporate Summary

Table 61. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 62. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 63. Ipsen Corporate Summary

Table 64. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 65. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 66. Sayre Therapeutics Corporate Summary

Table 67. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 68. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue

(US\$, Mn), (2017-2022)

Table 69. Jazz Corporate Summary

Table 70. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 71. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 72. Alnylam Corporate Summary

Table 73. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 74. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 75. Bausch Health Corporate Summary

Table 76. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 77. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 78. Acrotech Biopharma Corporate Summary

Table 79. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 80. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 81. Takeda Corporate Summary

Table 82. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 83. Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 84. Chiesi Farmaceutici Corporate Summary

Table 85. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 86. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

Table 87. Gilead Sciences Corporate Summary

Table 88. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Offerings

Table 89. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Liposomal and Lipid-based Nanoparticle Drug Segment by Type in 2021
- Figure 2. Liposomal and Lipid-based Nanoparticle Drug Segment by Application in 2021
- Figure 3. Global Liposomal and Lipid-based Nanoparticle Drug Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2021
- Figure 8. By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028
- Figure 12. US Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028
- Figure 16. Germany Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

2017-2028

Figure 21. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

Figure 24. China Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 28. India Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

Figure 30. Brazil Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2017-2028

Figure 33. Turkey Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Liposomal and Lipid-based Nanoparticle Drug Revenue, (US\$, Mn), 2017-2028

Figure 37. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Teva Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Liposomal and Lipid-based Nanoparticle Drug Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/LC9999DB22F3EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LC9999DB22F3EN.html>